AHA Opposed Rebate Models in SECURE 340B Act
Hospital leaders seek to maintain upfront drug discounts as Congress debates new 340B compliance requirements.
Updated on Sept. 25, 2026 in Healthcare
Live Poll
Should Congress mandate rebate bans to protect hospital cash flow in the 340B drug program?
The American Hospital Association has formally requested that Congress ban rebate models within the proposed SECURE 340B Act. The group contends that shifting to a rebate system would disrupt hospital cash flow while advocating for the maintenance of existing patient definition standards.
Why it matters
The AHA argues that rebate-based models create financial strain, while the proposed bill seeks to standardize 340B compliance through new reporting and audit mandates. These regulatory shifts could alter how healthcare providers manage drug savings and maintain outpatient operational eligibility.
The proposed SECURE 340B Act mandates a 4-year upfront discount pricing period and a 24-month window for outpatient visit qualification. These changes face pushback from the AHA regarding the potential impact on institutional cash flow and historical patient eligibility standards.
The players
American Hospital Association
A national trade organization representing thousands of hospitals and health systems that influences federal health policy and regulatory compliance.
Congress
The legislative body of the United States currently debating the SECURE 340B Act, which seeks to reform pharmacy drug pricing programs.
The details
The SECURE 340B Act introduces a national claims-level clearinghouse to monitor usage and requires hospitals to report annual savings metrics. The AHA supports the bill's contract pharmacy protections but warns that rigid patient definitions, which deviate from those in place since 1996, could exclude chronically ill populations from the program. Operators must monitor whether Congress retains the upfront discount mechanism or adopts the rebate model, which would fundamentally alter short-term liquidity management.
Timeline
The current HRSA patient definition standard was established in 1996.
The bipartisan SECURE 340B Act was introduced to Congress in July 2026.
The American Hospital Association submitted formal comments on September 23, 2026.
Market Landscape
The push to reform the 340B program follows decades of debate over the 1996 HRSA patient definition standards. By proposing new annual reporting metrics and a national clearinghouse, the current bill signals a pivot toward more centralized oversight of healthcare provider drug savings.
Hospital operators should prepare for potential increases in administrative burden related to reporting savings and compliance audits. Consult with internal legal counsel to assess how the proposed 24-month outpatient qualification window might impact current revenue cycle management.
The takeaway
The move toward a centralized claims clearinghouse represents a significant operational shift for 340B-participating institutions. Leadership should track upcoming congressional amendments regarding the recordkeeping mandates to adjust internal compliance workflows early.
Further reading
For broader context on current industry shifts, see Healthcare.
Live Poll
Should Congress mandate rebate bans to protect hospital cash flow in the 340B drug program?
